Thus, PLK1 inhibition normalized aberrant ZFP36/TTP activity in cancer cells, making PLK1‐mediated post‐transcriptional pathway and ZFP36/TTP phosphorylation promising targets for cancer therapy. Here, ZFP36 is linked to cancer.